Warfarin: The End or the End of One Size Fits All Therapy?
Pirmohamed M 
J Pers Med.2018 Jun 28 ; 8(3):.
PubMedで表示
Google翻訳で開く
(41view , 0users)
Full Text Sources
Oral anticoagulants are required for both treatment and prophylaxis in many different diseases. Clinicians and patients now have a choice of oral anticoagulants, including the vitamin K antagonists (of which warfarin is the most widely used and is used as the exemplar in this paper), and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban, and edoxaban). This paper explores the recent advances and controversies in oral anticoagulation. While some commentators may favour a complete switchover to DOACs, this paper argues that warfarin still has a place in therapy, and a stratified approach that enables the correct choice of both drug and dose would improve both patient outcomes and affordability.
PMID: 29958440 [PubMed]
PMID: 29958440 [PubMed]
関連論文
- [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
- Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
- Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
- [Review] Warfarin: The End or the End of One Size Fits All Therapy?